Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: A cost-of-illness study in Hong Kong

Rheumatology

Volumn 48, Issue 5, 2009, Pages 564-568

  Zhu, Tracy Y ^a   Tam, Lai Shan ^a   Lee, Vivian W Y ^b   Lee, Kenneth K ^b   Li, Edmund K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Cost of illness; Neuropsychiatric lupus; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISONE; PSYCHOTROPIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST OF ILLNESS; DRUG COST; FEMALE; HEADACHE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HONG KONG; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 65249137271     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep031     Document Type: Article

References (34)

1. Becker-Merok A, Nossent HC. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol 2006;33:1570-7.
2. Cook RJ, Gladman DD, Pericak D, Urowitz MB. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J Rheumatol 2000;27:1892-5.
3. Mok CC, Ho CT, Wong RW, Lau CS. Damage accrual in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2003;30:1513-9.
4. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
5. Hanly JG, McCurdy G, Fougere L, Douglas JA, Thompson K. Neuropsychiatric events in systemic lupus erythematosus: Attribution and clinical significance. J Rheumatol 2004;31:2156-62.
6. Hanly JG, Urowitz MB, Sanchez-Guerrero J et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study. Arthritis Rheum 2007;56:265-73.
7. Harel L, Sandborg C, Lee T, von Scheven E. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol 2006;33:1873-7.
8. Rood MJ, Breedveld FC, Huizinga TW. The accuracy of diagnosing neuropsychiatric systemic lupus erythematosus in a series of 49 hospitalized patients. Clin Exp Rheumatol 1999;17:55-61.
9. Jonsen A, Bengtsson AA, Nived O, Ryberg B, Sturfelt G. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: Increased morbidity but low mortality. Rheumatology 2002;41:1308-12.
10. Clarke AE, Panopalis P, Petri M et al. SLE patients with renal damage incur higher health care costs. Rheumatology 2008;47:329-33.
11. Clarke AE, Esdaile JM, Bloch DA, Lacaille D, Danoff DS, Fries JF. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993;36:1548-59.
12. Sutcliffe N, Clarke AE, Taylor R, Frost C, Isenberg DA. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology 2001;40:37-47.
13. Clarke AE, Petri M, Manzi S et al. The Systemic Lupus Erythematosus Tri-nation Study: Absence of a link between health resource use and health outcome. Rheumatology 2004;43:1016-24.
14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
15. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
16. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996;35:248-54.
17. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
18. Grant C. The Hong Kong health care system. Sydney: School of Health Services Management, University of New South Wales, 1998.
19. Leung GM, Bacon-Shone J. Hong Kong's health system: Reflections, perspectives and visions. Hong Kong: Hong Kong University Press, 2006.
20. Woo J, Lau E, Lau CS et al. Socioeconomic impact of osteoarthritis in Hong Kong: Utilization of health and social services, and direct and indirect costs. Arthritis Rheum 2003;49:526-34.
21. Zhu TY, Tam LS, Lee VW et al. Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Rheumatology 2008;47:1422-5.
22. Liljas B. How to calculate indirect costs in economic evaluations. Pharmaco-economics 1998;13:1-7.
23. Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 1996;156: 1337-44.
24. Friedman AW, Alarcon GS, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. LUMINA Study Group. Lupus in Minority Populations, Nature versus Nurture. Arthritis Care Res 1999;12:256-66.
25. Tam LS, Wong A, Mok VC et al. The relationship between neuropsychiatric, clinical, and laboratory variables and quality of life of Chinese patients with systemic lupus erythematosus. J Rheumatolo 2008;35:1038-45.
26. Kozora E, Ellison MC, Waxmonsky JA, Wamboldt FS, Patterson TL. Major life stress, coping styles, and social support in relation to psychological distress in patients with systemic lupus erythematosus. Lupus 2005;14:363-72.
27. Nery FG, Borba EF, Hatch JP, Soares JC, Bonfa E, Neto FL. Major depressive disorder and disease activity in systemic lupus erythematosus. Compr Psychiatry 2007;48:14-9.
28. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001;57: 496-500.
29. Sanna G, Bertolaccini ML, Cuadrado MJ et al. Neuropsychiatric manifestations in systemic lupus erythematosus: Prevalence and association with antiphospholipid antibodies. J Rheumatol 2003;30:985-92.
30. Hanly JG. Neuropsychiatric lupus. Rheum Dis Clin North Am 2005;31:273-98, vi.
31. Brey RL, Holliday SL, Saklad AR et al. Neuropsychiatric syndromes in lupus: Prevalence using standardized definitions. Neurology 2002; 58:1214-20.
32. Mok CC, To CH, Mak A. Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus. Medicine 2006;85:221-8.
33. Mok CC, Lau CS, Wong RW. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2001;28:766-71.
34. Sanna G, Bertolaccini ML, Khamashta MA. Neuropsychiatric involvement in systemic lupus erythematosus: Current therapeutic approach. Curr Pharm Des 2008;14: 1261-9.